All In MedTech

FDA Clearance Tracker · P220025-S001

LimFlow System

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Oct 12, 2023 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Oct 12, 2023

Approved

Time to decision

27 days

Received Sep 15, 2023. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track No User Fee

Device class

Class III

The decision

FDA number
P220025-S001
Device name
LimFlow System
Applicant
LimFlow, Inc.
Applicant location
San Jose, CA
Received
Sep 15, 2023
Decided
Oct 12, 2023
Decision
Approved
Supplement type
Normal 180 Day Track No User Fee
Reason for supplement
Postapproval Study Protocol
Original approval
P220025

Device type

Device class
Class III

Every decision under product code QWN

FDA's approval statement

As written in FDA's record.

Approval of the protocol for the post-approval study (PAS) referenced above. The PAS protocol has been submitted to comply with the conditions of approval outlined in our approval order for P220025.

Source documents

Other decisions for LimFlow, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

6 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.